Novartis AG
USE OF IL-1BETA BINDING ANTIBODIES

Abstract:

Use of an IL-1.beta. binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of a cancer having at least a partial inflammatory basis.